Skip to content GentiBio
  • About
    • Company Overview
    • Our Investors
    • Our Team
  • Our Approach
    • Treg Platform
    • Off-the-shelf Allo
    • Scalable Manufacturing
  • Pipeline & Programs
    • Our Pipeline
    • GNTI-122 – T1D (POLARIS)
    • GNTI-148 – T1D
    • GNTI-932 – IBD
    • GNTI-350 – B/T cell-driven AID
    • GNTI-823 – Acute Inflammatory
  • News
    • Genti in the News
    • Publications
    • Conference Presentations
  • Contact
    • Locations
    • Careers
GentiBio Mobile Menu Toggle navigation
GentiBio
  • About
    • Company Overview
    • Our Investors
    • Our Team
  • Our Approach
    • Treg Platform
    • Off-the-shelf Allo
    • Scalable Manufacturing
  • Pipeline & Programs
    • Our Pipeline
    • GNTI-122 – T1D (POLARIS)
    • GNTI-148 – T1D
    • GNTI-932 – IBD
    • GNTI-350 – B/T cell-driven AID
    • GNTI-823 – Acute Inflammatory
  • News
    • Genti in the News
    • Publications
    • Conference Presentations
  • Contact
    • Locations
    • Careers
Genti Pipeline
GentiBio

© 2026 GentiBio

  • Terms and Conditions
  • Privacy Policy
  • FCOI Policy
  • Expanded Access Policy
  • Twitter
  • LinkedIn